According to Government sources, the National Task Forces on Covid 19 has dropped Ivermectin and Hydroxychloroquine from the clinical guidelines for managing adult Covid-19 patients.
Usage of Ivermectin and Hydroxychloroquine
In December 2019, patients admitted with pneumonia secondary exposed to a new subtype of Coronavirus (COVID-19) were identified in China.
A few months later, the virus spread worldwide and resulted in million deaths so, WHO declared a pandemic.
Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. There was no proven treatment to this, so lockdown became necessary.
In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and Hydroxychloroquine) had antiviral activity and increased viral clearance.
On the other hand, Ivermectin has been shown in vitro to reduce viral replication and, in an observational cohort, more incredible viral support with promising clinical results.
So far, there is no standard of treatment, and clinical trials are needed to find effective treatment alternatives.
Objective: To evaluate the safety and efficacy of treatment with Hydroxychloroquine and Ivermectin for serious COVID-19 infections in no critical hospitalized patients.
Material and methods: Randomized controlled trial of patients diagnosed with the respiratory disease by COVID-19, who present criteria for hospitalization.
Doctors provided randomization to receive Hydroxychloroquine at a dose of 400 mg every 12 hours for one day and 200 mg every 12 hours to complete a 5-day treatment schedule.
Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day.
Group 3: Placebo. Before randomization, the risk of cardiovascular complications determined by corrected QT interval related to hydroxychloroquine intake will be assessed.
If the patient is at high risk, the allocation will be to Ivermectin only or placebo in independent randomization; if the risk is low, any three groups could be assigned.
The safety outcomes will be the requirement of mechanical intubation, septic shock or death.
Viral clearance will also be evaluated using PCR, taken on the 5th day after admission, days 14 and 21.
Current Covid Situation
On Friday, 24th September, Indian media reported that India crossed 31,382 new Covid-19 cases and 318 deaths within the past 24 hours.
The country now has 3,00,162 Covid-cases under the active case list, which is practically the lowest in 188 days.
The country faces an unprecedented recovery rate at 97.78%, again the highest since March 2020.
32,542 people have been discharged in the last 24 hours, which counts 32,848,273 recovered people in total all over the country
Vaccine Doses
India has administered more than 84.15 crore vaccine doses till today, which tells more than 72.20lakh vaccine doses have been distributed in the last 24 hours.
Why Hydroxychloroquine and Ivermectin are harmful?
Medical examiners have asked to drop Hydroxychloroquine because they found that there are no mortality benefits in it.
Also, Hydroxychloroquine helps increase drug addiction and address drug effect (ADE) when co-administered with Azithromycin.
There are more harms than benefits, so that it will waste money, and health status can degrade.
Meanwhile, doctors showed the most critical fact that there’s no specific clinical recovery in those patients who have been using Ivermectin and Hydroxychloroquine.
For every patient suffering from Covid-19 these days, it is time for them to understand their health and what kind of medicines will help them recover.
The government has asked every hospital to take good care of the patients. Doing so, every responsible person in a hospital, from a nurse to a doctor to every health care specialist, has to remind of all the evil and harmful effects of Ivermectin and Hydroxychloroquine. Every citizen of this country needs to be aware of this news as soon as possible.
Also, the clinical guidance note dated 19th May 2021 was made jointly by AIIMS, ICMR NTF. Later, they reviewed a Joint Monitoring Group on 20th August in the context of emerging evidence for both the medicines.
They reported both the drugs, Ivermectin and Hydroxychloroquine, could be used with caution only during the climax trial setting; otherwise, these can be dangerous and can become the reason for one’s demise.
